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Results
Eight patients who received a liver transplant after AMC-BAL treatment are still alive under longterm pharmacological immunosuppression. The current clinical follow-up ranges from 5.6 to 8.7
years after BAL treatment.
A new q-real-time PCR assay has been developed and validated to detect PERV infection. The limit of quantification of PERV DNA was ≥ 5 copies per 1x10 5 PBMCs. The linear dynamic range was from 5x10 0 to 5x10 6 copies. In both patients and HCWs, neither PERV DNA in PBMCs nor PERV RNA in plasma and PBMC samples have been found. 
Conclusions

Introduction
Acute liver failure (ALF) is a rare, but devastating syndrome in which people with no previous history of liver disease can develop fatal liver disease within weeks of the first symptoms. In the USA and Europe each year more than 7.500 patients develop ALF. The majority of these patients die. ALF is characterised by massive liver cell death leading to loss of essential metabolic and synthetic functions and a deranged inflammatory response. Consequently, jaundice, bleeding, hepatic coma and multi-organ failure (MOF) develop rapidly.
The cause of ALF includes, among others, acute viral infections, such as hepatitis A, B and C, poisoning, and rare inherited metabolic diseases (1).
ALF has a high mortality rate: 50-90% (1) and in most cases liver transplantation (OLT) is the only treatment with proven efficacy. OLT is, however, not always possible because of the shortage of available organs for transplantation. However, there is a significant proportion of patients (20-40%) whose liver can recover if sufficient bridging time is provided.
For these reasons, a variety of extracorporeal hepatic assist devices has been developed to provide detoxification and/or metabolic support in patients with ALF (2).
The use of porcine liver cell-based extracorporeal support exposes the patients to the risk of xenogenic infectious agents. The major concern is the possibility of cross species transmission of porcine endogenous retroviruses (PERVs).
Pigs harbour many PERV sequences in their genome (3) (4) (5) (6) (7) (8) . It has been shown that PERVs are able to infect selected human cells in vitro (9) (10) (11) (12) (13) . Extra-corporeal plasma perfusion through BAL may imply an hypothetic transfer of PERV infective particles from porcine liver cells in bioreactors to patient' s plasma during treatment. The risk may be enhanced when patients receive liver transplant and are long-term pharmacologically immunosuppressed. Although no PERV infections have been found in non-human primates exposed to porcine cells or organs (14) (15) (16) (17) (18) (19) , neither in human recipients parenteral exposed to porcine organs nor cells in xenotransplantation clinical trials (20) (21) (22) (23) (24) (25) (26) (27) (28) , the most important regulatory agencies worldwide have designed very strict guidelines on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 µm pore size, and perfused through the bioreactor charged with 10 billions of viable porcine hepatocytes, as described elsewhere (32) ( Fig.1-2 ). This phase I clinical study in 14 ALF patients showed improvements in hemodynamics and diuresis, in the neurological state and several biochemical parameters and proved the safety of the treatment concerning the risk of transmission of PERV infection to patients. We found that patient's plasma samples collected at the end of BAL treatment were positive for PERV DNA, most probably due to porcine liver cell lysis. Furthermore, the PERV DNA was cleared within two weeks post- In the current study we evaluated the BAL treated patients who were chronically immunosuppressed after a post-treatment follow-up from 5.6 to 8.7 years. We used a new developed quantitative real-time PCR assay (q-real-time PCR) more sensitive than the previous one (33) . In addition we evaluated PERV infection in healthcare workers (HCWs) who were involved in preclinical and clinical phases of trial. In no patient and none of the HCWs PERV infection had occurred. This is the first report which supports the absence of PERV infection in transplant survivors who were long-term immunosuppressed after exposure to a porcine liver cell based bioartificial liver. 
Materials and Methods
Study population
Eight living patients treated with the AMC-BAL between 2000 and 2003 were included in the study. All were chronically immunosuppressed because of receiving a liver transplant from a few hours to a few days after BAL treatment. One living patient, who recovered after BAL treatment without the need for a graft, has not agreed to the study. Frozen PBMCs and plasma samples of one patient, who died two years after BAL treatment because of a second organ rejection, have been included in the study to exclude PERV infection at that time. As comparison to previously reported data (33), frozen plasma and PBMC samples, collected from each patient immediately after BAL treatment and at the first time point of follow-up, were also assessed in this study.
In addition thirteen HCWs frequently exposed to pig tissues or blood containing PERV genomes or to in vitro cultures of porcine kidney epithelial cells (PK-15) and human embryonic kidney cells (HEK-293) infected with PERV, were included in the study. This group includes two surgeons, two anesthesiologists and three nurses, four biologists, two virologists.
All patients and HCWs enrolled in the study signed a written informed consent.
Clinical specimens
Whole EDTA blood samples from patients and HCWs were centrifuged at 2.500 rpm for 5 min and plasma was stored at -80°C.
PBMCs were isolated from nine ml of whole blood by gradient centrifugation method using The concentrations of DNA or RNA were determined by measuring the absorbance at 260 nm (A260) using a spectrophotometer. PERV genomes were detected using a novel q-real-time PCR assay and the previously developed PCR ELISA assay (33) . Primers and probes of both assays were selected from the cloned PERV insert in p-PCR-PERV.
Construction of PERV containing plasmid (p-PCR-PERV)
Detection of PERV
PERV q-real-time PCR assay
Primers and probe used in q-real-time PCR assay were PERV 1-F, PERV 2-R, which amplifies a fragment of 95 bp, and PERV-TM probe (Table1). The q-real-time PCR assay was performed using follows: an initial step at 65°C for 10 min of random hexamer primer and isolated RNA, followed by addition of RT mixture and incubation at 55°C for 30 min, with a final step at 85°C for 5 min.
Two microliters of cDNA were added to the amplification mixture in a final volume of 20 microliters and the PCR was performed as described above.
Internal controls
Absence of inhibitors and efficiency of PCR were evaluated by amplification and detection of a 110
bp fragment of the human β-globin gene using LightCycler ® Control Kit DNA (Roche Diagnostics, Mannheim, Germany). Amplification and detection of 322 bp fragment of an in vitro transcribed 
PCR and RT-PCR ELISA assay
PCR and RT-PCR ELISA assays were performed as previously reported (33) 
Results
Validation of the q-real-time PCR assay
Primers PERV 1-F and PERV 2-R amplify a 95 bp amplicon internal to 151 bp amplicon of the plasmid PCR-PERV. Both amplicons showed a 100% of identity within PERV A, PERV B and PERV C pol gene sequences by using BLAST algorithm. Amplicons produced in the PCR reaction with PERV plasmid and PERV positive controls had the same melting temperature, certifying the specificity of the assay.
A standard curve was generated by 10-fold serial dilutions of PERV plasmid DNA containing from 5x10 6 to 5x10 0 copies/reaction mixture. A copy number of 5 x10 0 yielded an average threshold cycle (C t ) value of 33.95, whereas a copy number of 5x10 6 yielded a C t value of 15.32. Every 10-fold decrease in the copy number yielded an average increase of 3.10 in C t value. The linearity was obtained for the entire dilution range from 5x10 0 to 5x10 6 copies: slope -3.10, intercept 33.95, error 0.00200, efficiency 2.075, correlation coefficient -0.67041
To test the sensitivity of this method, triplicate serial dilutions of PERV plasmid DNA were added to DNA extracted from 1x10 5 PBMCs of healthy donors and tested by q-real-time PCR assay.
Eight concentration levels at approximately 1000, 200, 100, 50, 20, 10, 5, and 1 copies of PERV plasmid DNA were tested. The lowest concentration at which detection of PERV plasmid DNA occurred in ≥95% of replicates was used to define the detection limit of the assay.
Q-real-time PCR assay showed that 100% of replicates were positive up to 1 copy of PERV plasmid DNA in 5 µl of DNA solution or 10 copies in 50 µl of DNA solution corresponding to the total DNA extracted from 1x10 5 PBMCs. The amplification curve of one of three replicates is shown in Fig 3. The mean threshold cycles and standard deviations are shown in Table 2 . Standard curve assigned a mean concentration of 0.5 copies to the replicates containing approximately one copy of p-PCR-PERV in 5µl of human DNA solution. We concluded that our assay was capable to reliably detect ≥ 5 copies of PERV DNA /total DNA isolated from 1x10 5 PBMCs. (Fig. 4) . PERV DNA and RNA in PBMCs and plasma samples were negative at any points of follow up by using both q-real time PCR (Table 3) Since the AMC BAL does not allow direct contact between porcine cells loaded in the bioreactor and patient's blood cells and complement containing plasma is perfused, transmission of PERV seems to be very unlikely.
Patient follow-up
However, since it is well known that a retrovirus infection may have latency of many years before any symptoms occur, especially in immune compromised patients, it still remained worthwhile to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   14 exclude PERV infection in our patients and HCWs even after many years. Besides the less sensitive PCR ELISA we have used in the past, now a very sensitive q-real-time PCR assay was applied.
The lack of detection of PERV DNA in PBMCs and the absence of PERV RNA in PBMCs and plasma from treated patients up to 8.7 year follow-up, allow us to exclude PERV latent infection.
We now used a q-real-time PCR assay with high sensitivity and specificity, that also confirmed the absence of PERV RNA in the previous stored plasma samples, assessed by the less sensitive conventional PCR ELISA at that time (33) . Therefore this study excludes PERV transmission to liver transplanted patients after AMC-BAL treatment and subsequently pharmacological immunosuppression for many years.
We also confirm that the adherence to recommended infection control measures was sufficient to prevent PERV transmission to HCWs exposed to pig organ or cells during preparation and application of the AMC BAL.
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